DZ Bank’s Regulus Therapeutics RGLS Stock Holding History

DZ Bank’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,706	Closed	-$147K	–	1045
2018 Q1	$147K	Buy	+1,706	New	+$228K	﹤0.01%	965

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return

Ascend Capital Orinda, California $1.99B AUM 10.37% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

DZ Bank's RGLS Position: Q2 2018 in Review

DZ Bank sold out of Regulus Therapeutics (RGLS) in Q2 2018, closing a stake of 1,706 shares — an estimated $147K sold.

DZ Bank first reported a position in RGLS in Q1 2018 and held it in 1 quarter. The position peaked at $147K in Q1 2018. 46 funds tracked by Wall St. Rank hold RGLS as of Q2 2018.

DZ Bank reported no remaining Regulus Therapeutics position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 1,706 Regulus Therapeutics shares in Q2 2018, an estimated $147K.
DZ Bank first reported a position in Regulus Therapeutics in Q1 2018 and held it in 1 quarter.
DZ Bank's Regulus Therapeutics position peaked at $147K in Q1 2018.
46 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.